Pharma News

An antioxidant found in green tea may increase levels of p53, a natural anti-cancer protein, known as the “guardian of the genome” for its ability to repair DNA damage or destroy cancerous cells. Published today in Nature Communications, a study of the direct interaction between p53 and the green tea compound, epigallocatechin gallate (EGCG), points to a new target for cancer drug discovery.

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

XECH, India’s emerging innovator brand, has launched XECH STEROSTET – one-of-its-kind and India’s first Stethoscope Sterilizer which uses a special UV-C GI Technology to effectively sterilize stethoscopes diaphragms of all sizes up to 99.9999%.

Strides Pharma Science Limited (Strides) announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Prednisone Tablets USP, 10 mg and 20 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Deltasone Tablets, 10 mg and 20 mg, of Pharmacia and Upjohn Co. (Pharmacia).

Sun Pharmaceutical settled for a case pertaining to alleged violation of listing obligation and disclosure requirements norms with regulator Securities and Exchange Board of India (SEBI). The aggregate settlement charges were paid around Rs 2.9 crores.

The show cause notices issued by SEBI on May 19, 2020 to Sun Pharmaceutical Industries Limited, and the Whole-time Directors and certain officers at the relevant time.

Research over the last 20 years has shown that atherosclerosis is a chronic inflammatory condition of the arterial blood vessel wall. Soluble mediators such as cytokines and chemokines are pivotal players in this disease, promoting vascular inflammation. However, the development of anti-inflammatory therapeutics directed against such mediators that could prevent atherosclerosis has proven difficult, despite promising clinical studies in the recent past.

Inhibiting a key enzyme that controls a large network of proteins important in cell division and growth paves the way for a new class of drugs that could stop glioblastoma, a deadly brain cancer, from growing.

Researchers at Princess Margaret Cancer Centre, the Hospital for Sick Children (SickKids) and University of Toronto, showed that chemically inhibiting the enzyme PRMT5 can suppress the growth of glioblastoma cells.

Amid premature and incomplete reports from the World Health Organization’s (WHO) investigative team which has just concluded its work in China to discover the origins of SARS-CoV-2, AIDS Healthcare Foundation (AHF) calls for the investigation to continue and for the team to release a detailed report and hold a legitimate press conference after leaving China.

Individual choices in medicine carry a certain amount of uncertainty. An innovative partnership at The University of Texas at Austin takes aim at medicine down to the individual level by applying state-of-the-art computation to medical care.

"Medicine in its essence is decision-making under uncertainty, decisions about tests and treatments," said Radek Bukowski, MD, PhD, professor and associate chair of Investigation and Discovery in the Department of Women's Health at Dell Medical School at UT Austin.